{"disease":{"id":"liver-cancer-of-non-resectable","name":"liver cancer of non resectable"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04090645","title":"TheraSphere & Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":187,"lead_sponsor_name":"Methodist Health System","has_results":false},{"nct_id":"NCT03239158","title":"Bioinformation Therapy for Liver Cancer","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Fuda Cancer Hospital, Guangzhou","has_results":false},{"nct_id":"NCT05497453","title":"A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":24,"lead_sponsor_name":"Omega Therapeutics","has_results":false},{"nct_id":"NCT03563274","title":"QuiremSpheres Observational Study","phase":"","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Terumo Europe N.V.","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}